financetom
Business
financetom
/
Business
/
Sonos Q3 revenue beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sonos Q3 revenue beats estimates
Aug 6, 2025 1:39 PM

Overview

* Sonos ( SONO ) fiscal Q3 revenue beats high end of guidance

* Adjusted EPS for fiscal Q3 beats analyst expectations, per LSEG data

* Adjusted EBITDA for fiscal Q3 beats analyst estimates, per LSEG data

Outlook

* Company to provide guidance on Third Quarter Fiscal 2025 earnings call

* Sonos ( SONO ) highlights tariffs and macroeconomic uncertainty as challenges

Result Drivers

* EXPENSE DECLINES - Significant year-over-year expense declines contributed to adjusted EBITDA at high end of guidance, per CFO Saori Casey

* SOLID EXECUTION - Revenue exceeded guidance due to solid execution amidst tariffs and macroeconomic uncertainties, according to CFO Saori Casey

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $344.76 $324.80

Revenue mln mln (2

Analysts

)

Q3 Beat $0.19 -$0.1 (2

Adjusted Analysts

EPS )

Q3 Beat $22.60 -$18.90

Adjusted mln mln (1

Net Analyst)

Income

Q3 Net -$3.38

Income mln

Q3 Beat $36 mln $16.60

Adjusted mln (2

EBITDA Analysts

)

Q3 -$2.93

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the household electronics peer group is "hold."

* Wall Street's median 12-month price target for Sonos Inc ( SONO ) is $12.25, about 11.3% above its August 5 closing price of $10.86

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alkami Q4 Loss Narrows, Revenue Rises; Initiates 2025 Guidance
Alkami Q4 Loss Narrows, Revenue Rises; Initiates 2025 Guidance
Feb 27, 2025
05:14 PM EST, 02/27/2025 (MT Newswires) -- Alkami Technology ( ALKT ) posted a Q4 diluted loss Thursday of $0.08 per share, narrowing from a loss of $0.13 a year earlier. Analysts polled by FactSet also expected a loss of $0.08. Revenue for the quarter ended Dec. 31 was $89.7 million, up from $71.4 million. Analysts surveyed by FactSet expected...
Rtx Insider Sold Shares Worth $2,464,253, According to a Recent SEC Filing
Rtx Insider Sold Shares Worth $2,464,253, According to a Recent SEC Filing
Feb 27, 2025
05:12 PM EST, 02/27/2025 (MT Newswires) -- Ramsaran Maharajh, Executive Vice President and General Counsel, on February 25, 2025, sold 19,431 shares in Rtx (RTX) for $2,464,253. Following the Form 4 filing with the SEC, Maharajh has control over a total of 33,592 common shares of the company, with 29,742 shares held directly and 3,850 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/101829/000122520825002580/xslF345X05/doc4.xml...
Xenon Pharmaceuticals Q4 Net Loss Widens
Xenon Pharmaceuticals Q4 Net Loss Widens
Feb 27, 2025
05:12 PM EST, 02/27/2025 (MT Newswires) -- Xenon Pharmaceuticals ( XENE ) reported a Q4 net loss late Tuesday of $0.84 per diluted share, widening from a loss of $0.64 a year earlier. Analysts polled by FactSet expected a loss of $0.88. No revenue was recorded in the three months ended Dec. 31, as expected. The company had $754.4 million...
Crinetics Pharmaceuticals Q4 Net Loss Narrows
Crinetics Pharmaceuticals Q4 Net Loss Narrows
Feb 27, 2025
05:14 PM EST, 02/27/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported a Q4 net loss late Thursday of $0.88 per diluted share, narrowing from the loss of $0.90 a year earlier. Analysts polled by FactSet expected a loss of $0.89. No revenue was reported for the quarters that ended Dec. 31 in 2023 and 2024. Analysts surveyed by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved